On November 13, CANSINOBIO fell 4.02% in Regular Trading, trading at HK$24.86, with turnover of HK$30.51 million.

The most recent public-information backdrop shows no stronger new catalyst beyond routine corporate filings and previously released quarterly results, while the stock has pulled back as the market continues to digest earlier developments and sector sentiment.

Recent disclosures showed October share capital unchanged at 247,043,801 shares in total, with no new issuance, repurchase, or cancellation. The company also changed one ongoing sponsor representative, a governance-related adjustment that does not alter operations. Earlier, its third-quarter report showed revenue of RMB882 million for the first nine months, up 27.40% year on year, and attributable net profit of RMB16.29 million, up 12.82%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)